37Point9 Announces Major Joint Partnership China Medical Opportunity to Worldwide Medical Industry Plus Update on Current Acquisition Program.

Business Editors & Health/Medical Writers

SAN DIEGO--(BW HealthWire)--Aug. 13, 2002

37Point9 (OTCBB:TSPN) stated today that its joint partnership program for China will be announced this week through Biomedical Market News Service and its Biomedical Market Newsletter. This will be accomplished through its highly respected Medical Industry E-mail News Service.

According to Medical Industry E-mail Services, they "reach over 120,000 individual e-mail addresses of medical industry executives worldwide." They further state that their "`pass-around e-mail forwarding' generates readership of approximately 300,000 - 500,000 persons in some 150 countries. The readership includes highly valuable middle to top management key executives, decision makers and regulatory affairs professionals at practically every medical product manufacturer. Well over 250 leading medical trade associations, major universities, medical publishers and medical product manufacturing/service provider companies use our E-mail News Service on a regular basis."

International Medical Ventures will coordinate the project for 37Point9. They have selected Stephen Burns to be their Field Project Manager. Burns, a well recognized personnel and consultant recruiter in the medically related software industry, recently assisted in the merger of a shell corporation with a chain of non-invasive back medical and surgery clinics. His experience not only in recruiting but in the merger-acquisition arena will be of high benefit to 37Point9's Joint Partnership Program.

Bruce W. Barren, 37Point9's lead consultant, has developed relationships in China that are capable of performing the manufacturing plus sales and marketing of product licensing relationships. The Joint Partnership Program licensing will require limited capital since 37Point9 will provide the services through existing relationships developed by Barren and his associates in China. The products will be supplied by 37Point9's partners in this relationship.

Doug Brown, President of 37Point9, stated, "This major thrust toward developing licensing program partnerships should show all investors that 37Point9 is fully committed to developing such an extensive program, available worldwide with initial focus on China."

Further, Brown said, "As financing will in no way hinder the completion of these licensing partnership programs, this should show our shareholders and the investment community that any questions or uncertainties that have recently arisen as to 37Point9's ability to develop into a successful medical products company with an emphasis in China are nothing more than myth. As each partnership agreement is reached, announcements will be made.

"The first distribution acquisition is scheduled for September when Barren returns to China. Once this is completed we will have the true definition of our concept -- U.S. to China and China to U.S. Also scheduled for September is the acquisition of a medical software company which, by then, should have received a multi-million dollar contract from a U.S. fortune 100 company. This is an enlargement of an existing contract with an affiliate of the acquisition company."

According to Brown, the Joint Partnership Program involves a 7-step process:

1. The partner will bring to 37Point9 an F.D.A. approved product

preferably in the cardiovascular area.

2. 37Point9 will evaluate and test market the potential for

China.

3. The partner will then give 37Point9 a license to manufacture

and sell.

4. 37Point9 will then prepare the Chinese State Drug

Administration (SDA) application. This is the Chinese

equivalent to the F.D.A.

5. 37Point9 applies for the licenses required to manufacture and

sell the products.

6. We then sell the products.

7. Profits from sales are received by Joint Venture Partner for

distribution.

Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. 37Point9 disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services and changes in our business strategies.